Cotización Aim Immunotech - 0A4Y

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Último Precio

Postura de Compra

0.00

Postura de Venta

0.00

Volume Operado de la Acción

0.00 Rango del Día 0.00

0.00 Rango de 52 semanas 0.00

Capitalización de Mercado [m]

Precio Anterior

0.00

Precio de Apertura

Hora

0.2105

(O)

Última hora de negociación

Volumen financiero

Precio Promedio Ponderado

Volumen promedio (3 m)

Acciones en circulación

48,842,000

Rendimiento del Dividendo

Ratio Precio/Utilidad

-3.04

Beneficio por acción (BPA)

-0.59

turnover

202k

Beneficio neto

-28.96M

Sector

Biological Pds,ex Diagnstics

Industria

Biological Pds,ex Diagnstics

Sitio web

www.aimimmuno.com

Sede

Wilmington, Delaware, USA

Fundado

Aim Immunotech Inc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker 0A4Y. The last closing price for Aim Immunotech was US$0. Over the last year, Aim Immunotech shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Aim Immunotech currently has 48,842,000 shares in issue. Aim Immunotech has a price to earnings ratio (PE ratio) of -3.04.

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue

AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue OCALA, Fla., Dec. 12, 2024 (GLOBE...

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer Preliminary finding of stable disease in two...

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast OCALA, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE...

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen® OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today...

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer Next safety cohort to...

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer OCALA, Fla...

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Year marked by growing body of promising data demonstrating Ampligen’s potential to address...

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast OCALA, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- AIM...

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research Data demonstrate...

AIM ImmunoTech Announces Launch of CEO Corner Platform

AIM ImmunoTech Announces Launch of CEO Corner Platform CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress Provides interested parties...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

0A4Y - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Aim Immunotech?

El precio actual de las acciones de Aim Immunotech es US$ 0.00

¿Cuántas acciones de Aim Immunotech están en circulación?

Aim Immunotech tiene 48,842,000 acciones en circulación

¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Aim Immunotech?

Aim Immunotech ha negociado en un rango de US$ 0.00 a US$ 0.00 durante el último año

¿Cuál es el ratio PE (precio/beneficio) de Aim Immunotech?

El ratio precio/beneficio de Aim Immunotech es -3.04

¿Cuál es el ratio de efectivo a ventas de Aim Immunotech?

El ratio de efectivo a ventas de Aim Immunotech es 439.02

¿Cuál es la moneda de reporte de Aim Immunotech?

Aim Immunotech presenta sus resultados financieros en USD

¿Cuál es el último ingresos anual de Aim Immunotech?

El último ingresos anual de Aim Immunotech es USD 202k

¿Cuál es el último beneficio anual de Aim Immunotech?

El último beneficio anual de Aim Immunotech es USD -28.96M

¿Cuál es la dirección registrada de Aim Immunotech?

La dirección registrada de Aim Immunotech es 251 LITTLE FALLS DRIVE, NEW CASTLE, WILMINGTON, DELAWARE, 19808

¿Cuál es la dirección del sitio web de Aim Immunotech?

La dirección del sitio web de Aim Immunotech es www.aimimmuno.com

¿En qué sector industrial opera Aim Immunotech?

Aim Immunotech opera en el sector BIOLOGICAL PDS,EX DIAGNSTICS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
NFXNuformix Plc	0.115p (84.00%)	169.13M
CHFChesterfield Resources Plc	0.40p (32.45%)	276.93k
IMMImmupharma Plc	5.20p (28.40%)	49.53M
SNGSynairgen Plc	2.70p (24.14%)	2.31M
GOODGood Energy Group Plc	480.00p (21.52%)	902.4k
DARDar Global Plc	US$ 6.00 (-22.83%)	6.98k
CLAICel Ai Plc	0.345p (-21.59%)	28.34M
CTAICatenai Plc	0.21p (-17.65%)	87.41M
GENIGenincode Plc	4.00p (-16.67%)	1.44M
WBIWoodbois Limited	0.095p (-15.56%)	222.83M
UKOGUk Oil & Gas Plc	0.0205p (-4.65%)	802.36M
CLONClontarf Energy Plc	0.045p (12.50%)	689.68M
SYMESupply@me Capital Plc	0.0025p (-13.79%)	415.74M
TRPTower Resources Plc	0.0295p (0.00%)	411.68M
NTVONativo Resources Plc	0.0021p (0.00%)	324.32M